FDA approves antibody-directed cytotoxic agent for acute myeloid leukemia.
Miller
J L
JL
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD / Q000276:immunology / Q000627:therapeutic use; D015214:Antigens, Differentiation, Myelomonocytic / Q000276:immunology / Q000627:therapeutic use; D000079982:Gemtuzumab; D006801:Humans; D000922:Immunotoxins / Q000008:administration & dosage / Q000627:therapeutic use*; D007951:Leukemia, Myeloid / Q000628:therapy*; D063268:Sialic Acid Binding Ig-like Lectin 3; D014481:United States; D014486:United States Food and Drug Administration
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; C571163:CD33 protein, human; D000922:Immunotoxins; D063268:Sialic Acid Binding Ig-like Lectin 3; D000079982:Gemtuzumab